 Stratum 3: Pediatric patients with recurrent or progressive tumors thought to involve the rasrafMAP pathway but not included in strata 1 or 2. This includes any LGG not included in strata 1 or 2 i.e., any LGG without a BRAF truncated fusion in a patient without NF1, any tumor other than LGG in a patient with NF1, and any other tumor with a known activating BRAF, NRAS or KRAS mutation. 